Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    orellanine
Previous Study | Return to List | Next Study

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05287945
Recruitment Status : Not yet recruiting
First Posted : March 18, 2022
Last Update Posted : July 6, 2022
Sponsor:
Information provided by (Responsible Party):
Oncorena AB

Brief Summary:
A phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma. The study will include an intra-patient dose escalation phase, followed by a dose expansion phase.

Condition or disease Intervention/treatment Phase
Carcinoma, Renal Cell Drug: Orellanine Phase 1 Phase 2

Detailed Description:
This is an open, non-controlled, phase I/II study evaluating the safety, tolerability, and anti-tumor efficacy of orellanine treatment in patients with metastatic clear-cell or papillary renal carcinoma. The study will include up to 40 patients. The study will consist of 2 phases: an intra-patient dose escalation phase, followed by a dose expansion phase. The dose escalation phase is designed to define maximum tolerated dose utilizing 3+3 study design or the dose producing complete response in ≥2 patients and enable a subsequent phase in which safety and efficacy can be measured in a more standardized manner. A safety review will be completed by the Data Review Committee after every dose in every patient in the dose escalation phase to review pharmacokinetics, safety and tolerability data. In the expansion part of the study (phase II), additional patients (≤20) will be recruited and treated at the RP2D to better characterize drug safety, tolerability, and preliminary efficacy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II, Open-Label, Single-Arm Study on Safety, Tolerability and Anti-Tumour Efficacy of Orellanine Treatment in Patients With Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Estimated Study Start Date : July 1, 2022
Estimated Primary Completion Date : November 1, 2023
Estimated Study Completion Date : July 1, 2024


Arm Intervention/treatment
Experimental: Orellanine 0.05-4.9 mg/kg single intravenous administration following hemodialysis Drug: Orellanine
single intravenous administration of orellanine over 30 (±5 minutes) following hemodialysis




Primary Outcome Measures :
  1. The occurrence of dose-limiting toxicities, treatment-emergent adverse events, and serious adverse events related to orellanine, [ Time Frame: Through study completion, approximately 1 year ]
  2. Determination of maximum tolerated dose. [ Time Frame: Through study completion, approximately 1 year ]
  3. Determination of recommended phase 2 dose. [ Time Frame: Through study completion, approximately 1 year ]

Secondary Outcome Measures :
  1. Efficacy of orellanine based on response rate and objective response rate at the end of the second cycle with administration of orellanine at the recommended phase 2 dose [ Time Frame: Through study completion, approximately 1 year. ]
  2. Efficacy of orellanine based on time to tumor response [ Time Frame: Through study completion, approximately 1 year. ]
  3. Efficacy of orellanine based on best overall response [ Time Frame: Through study completion, approximately 1 year. ]
  4. Area under the curve extrapolated to infinity [ Time Frame: Through study completion, approximately 1 year. ]
  5. Half-life [ Time Frame: Through study completion, approximately 1 year. ]
  6. Partial area under the curve [ Time Frame: Through study completion, approximately 1 year. ]
  7. Dose proportionality [ Time Frame: Through study completion, approximately 1 year. ]
  8. Time to maximum plasma concentration [ Time Frame: Through study completion, approximately 1 year. ]
  9. Maximum plasma concentration [ Time Frame: Through study completion, approximately 1 year. ]
  10. Total body clearance [ Time Frame: Through study completion, approximately 1 year. ]
  11. Volume of distribution [ Time Frame: Through study completion, approximately 1 year. ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provided written informed consent.
  • Diagnosis of histologically confirmed advanced ccRCC or pRCC with progression or intolerance to all standard therapies for which the patient is eligible. There is no limit to the number of prior treatments.
  • Measurable disease per RECIST version 1.1 criteria.
  • ECOG performance status of 0 - 2.
  • Age ≥18 years.
  • Life expectancy ≥3 months.
  • Acceptable hematologic laboratory values defined as:

    1. Neutrophils ≥1.5 × 10^9/L, without growth factor stimulation within 3 weeks prior to the blood test;
    2. Platelets ≥100 × 10^9/L;
    3. Haemoglobin ≥5.9 mmol/L (~9.5 g/dL), without transfusion within 4 weeks prior to the blood test. Use of erythropoietic is permitted.
  • Must be on chronic haemodialysis (on a consistent regimen for the previous three months, with allowance for intermittent treatments as required for volume overload).
  • The patient's treating nephrologist and oncologist agree that the prospect of loss of remaining renal function resulting from this treatment will not significantly change the patients' future and chronic dialysis treatment.
  • Female patients of child-bearing potential and male patients must agree to use 2 forms of highly effective contraception for the duration of study treatment and after the last dose of orellanine for at least 3 months for males and 6 months for females.
  • For females of child-bearing potential, a negative serum pregnancy test at screening.
  • Patients who are willing and able to comply with travel requirements, scheduled visits, treatment schedule, efficacy assessments, laboratory tests, and other study procedures.

Exclusion Criteria:

  • Diagnosis of any other malignancy within 2 years prior to enrolment, except for adequately treated basal cell or squamous cell skin cancer, superficial melanoma, or carcinoma in situ of the breast or of the cervix, or low grade (Gleason 7 or below) prostate cancer on surveillance with no plans for treatment intervention (e.g., surgery, radiation, or castration).
  • Has symptomatic, steroid-dependent, or progressive brain metastasis / metastases. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during trial screening), clinically stable, and without requirement of steroid treatment for at least 14 days prior to first dose of trial treatment.
  • Radiotherapy within 4 weeks before first dose.
  • Systemic anti-cancer therapy within 4 weeks before first dose.
  • Has not recovered from AEs due to prior anti-cancer medications to at least grade 1 by CTCAE version 5.0 (except for alopecia and grade 2 neuropathy).
  • Has received any other investigational product (IP) within 4 weeks before first dose.
  • Pregnant or breastfeeding women.
  • Uncontrolled medical condition including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements, or would, in the opinion of the investigator, place the patient at increased risk.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05287945


Contacts
Layout table for location contacts
Contact: Jeffrey Yachnin +46700856708 jeffrey.yachnin@regionstockholm.se

Sponsors and Collaborators
Oncorena AB
Publications:

Layout table for additonal information
Responsible Party: Oncorena AB
ClinicalTrials.gov Identifier: NCT05287945    
Other Study ID Numbers: ONC001-CL-001
First Posted: March 18, 2022    Key Record Dates
Last Update Posted: July 6, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Pursuant to relevant data protection and privacy legislation, patients will authorize the collection, use and disclosure of their study data by the investigator and by those persons who need that information for the purposes of the study.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Renal Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases